- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00645489
A Family Intervention for Improving Self-Care of Patients With Heart Failure
January 4, 2010 updated by: US Department of Veterans Affairs
This is a pilot study of a family-based educational program for patients with heart failure, and their family members.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- Objectives(s): We plan to conduct a feasibility pilot trial of the Family Partnership Intervention (FPI) compared to patients in the HF Wait-list (WL) condition. We plan to demonstrate feasibility, estimate variances of major outcome variables, and to obtain preliminary estimates of effect sizes in preparation for subsequent grant applications. We will be able to develop a cost-effectiveness model for the relative benefit of FPI vs. no family-based for use in longer-term studies.
- Research Design: This is a short-term, randomized clinical trial which will involve assessments for participants in the FPI condition at a pre-intervention Baseline point, immediately post-intervention, and 6 months post-intervention. Participants in the WL condition will be assessed at Baseline, undergo an approximately 8 week waiting period, and then the FPI. A longer follow-up is not planned based on the purpose of this study as a feasibility trial.
- Methodology: We plan to randomize 40 Veterans and their family members to either the FPI condition or WL condition, in equal proportions. We will recruit patients with at least Stage C Heart Failure (NYHA class I - IV) from the Cardiology clinic of the Philadelphia VAMC. FPI will involve 4-6 hours of intervention delivered over a period of 6-8 weeks. Assessments at a pre-treatment baseline point, 8 weeks (immediately post-treatment), and 6 months will cover the following domains: a) patients' demographic characteristics and clinical functioning, b) self-care, including self-management of symptoms, knowledge of HF, and adherence to medication and dietary intake of sodium, c) measures of family functioning relevant to the medical care of the patient, and d) health care utilization costs. Primary outcome measures will be patients' self-reported HF self-care and health care utilization costs. We anticipate that patients in the FPI condition will exhibit better self-care over time compared to patients in the WL condition. We also anticipate that patients and family members will exhibit an improved family environment and better HF knowledge.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- VA Medical Center, Philadelphia
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Stage C Heart Failure,[34] which refers to past or current symptoms of heart failure with underlying structural heart disease. Indicated by chronic systolic dysfunction (left ventricle [LV] ejection fraction < 45%), diastolic dysfunction (with echo evidence of diminished compliance of the LV), or both.
- The patient's cardiologist has recommended or initiated one of the following to prevent decompensation: continuing diuretic treatment, fluid restrictions, and/or restriction/reduction of dietary sodium intake.
- A family member or members available for study participation with whom patient lives for at least 5 days a week. Emphasis will be given to the closest family members available (i.e., spouse).
- Subjects are able to give informed consent (see below for exclusion due to well-documented dementia or evidence of cognitive impairment).
- Patients will be age 50 or above. Younger patients may have a different family environment than the most common type of patient who is the target of the FPI intervention.
Exclusion Criteria:
- Patient has a well-documented diagnosis of dementia
- Moderate or greater cognitive impairment, based on the Blessed Test of Orientation, Memory, and Concentration (BOMC)[26] score of 16.
- Patient's family member has BOMC score of 10 (i.e., mild or greater cognitive impairment).
- Inability to communicate verbally, major visual impairment, uncorrected hearing loss.
- Patient and/or family member reports "frequent use" illicit substance abuse within the past year. Scores on the AUDIT-C 4 indicating alcohol abuse/dependence.[30]
- Patient or family member has a current diagnosis of schizophrenia spectrum psychiatric disorder (e.g., schizophrenia, schizoaffective disorder).
- Patient indicates active suicidal ideation and evaluated as a clinical risk.
- Patient is in the Philadelphia VAMC home-telehealth program or some other incompatible intervention.
- Patient has an unstable medical condition that would likely prevent the subject from completing the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: 1
Control condition is wait-list control.
|
Wait list
|
|
Experimental: 2
Active treatment condition: psychoeducational intervention for patients with HF
|
Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
dietary sodium intake
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
medication adherence
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Steven L. Sayers, PhD, VA Medical Center, Philadelphia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (Actual)
March 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
March 24, 2008
First Submitted That Met QC Criteria
March 26, 2008
First Posted (Estimate)
March 27, 2008
Study Record Updates
Last Update Posted (Estimate)
January 6, 2010
Last Update Submitted That Met QC Criteria
January 4, 2010
Last Verified
December 1, 2008
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MIRECC002
- 0008
- 01008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure, Congestive
-
Indiana UniversityRecruitingCongestive Heart Failure | Congestive Heart Failure (CHF) | Congestive Heart Failure Chronic | Congestive Heart Failure(CHF)United States
-
Adnan Kastrati, MDBiotronik SE & Co. KGCompleted
-
Signature Medical, Inc.WithdrawnHeart Failure,Congestive
-
Nihon KohdenTerminatedHeart Failure,CongestiveUnited States
-
ELA Medical, Inc.Approved for marketing
-
Abbott Medical DevicesCompletedCongestive Heart Failure TreatedItaly
-
Echosense Ltd.Terminated
-
Echosense Ltd.WithdrawnCongestive Heart Failure (CHF)United States
-
Corthera, Inc.(formerly BAS Medical, Inc.), a member...TerminatedCongestive Heart Failure (CHF)Russian Federation
-
Meir Medical CenterUnknown
Clinical Trials on wait list
-
New York State Psychiatric InstituteCompletedCognitive Deterioration | Disorder of AgingUnited States
-
New York State Psychiatric InstituteFeinstein Institute for Medical ResearchCompleted
-
University of OsloNorwegian Institute of Public Health; Norwegian Council for Mental Health; The...CompletedQuality of Life | Wellbeing | Health AttitudeNorway
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Region VästmanlandKarolinska Institutet; Uppsala University; Uppsala County Council, Sweden; University... and other collaboratorsEnrolling by invitationStress | Occupational Health | Cost-effectiveness | Patient Safety | Quality of Care | Sick Leave | Preventable Adverse Events | Worker Health | Safety Culture | Productivity LossSweden
-
Fundación para la Investigación del Hospital Clínico...Completed
-
i4HealthCompleted
-
Stanford UniversityCompletedAutism Spectrum DisorderUnited States
-
University of Alabama at BirminghamNational Cancer Institute (NCI)Completed
-
Kaohsiung Medical University Chung-Ho Memorial...Kaohsiung Medical UniversityUnknownHead and Neck CancerTaiwan